On December 3, 2024, Shanghai Escugen Biotechnology Co., Ltd. (hereinafter referred to as "Escugen") announced that the company's independently developed innovative drug, ESG401 Injection, has received approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) to conduct its second Phase III clinical study (ESG401-302). This study focuses on the treatment of locally advanced, recurrent, or metastatic PD-L1 negative triple-negative breast cancer (TNBC) that has not previously been treated with systemic therapy.

On November 27, 2024, a research team led by Professor Qiu Fuming from the Second Affiliated Hospital of Zhejiang University School of Medicine published a case report titled "Case report: Prolonged benefit of ESG401, a Trop2 antibody-drug conjugate, in endocrine-refractory hormone receptor-positive, HER-2 negative metastatic breast cancer" in the oncology-focused journal Frontiers in Oncology.